Amgen (NASDAQ:AMGN) (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease. Notable marketed medicines developed or commercialized by the company include epoetin and darbepoetin products for anemia, granulocyte colony-stimulating factor therapies for infection risk reduction, bone-targeting agents for osteoporosis and skeletal complications, and a PCSK9 inhibitor for lipid management. The company also develops and markets biosimilars and newer targeted therapies emerging from its research programs.
Research and development is a core activity at Amgen, combining laboratory science, clinical trials and manufacturing capabilities to advance novel biologics and biosimilars. The company operates large-scale biologics manufacturing facilities and maintains a global commercial presence, selling products in North America, Europe, Asia-Pacific and other markets through its own commercial organization and in partnership with other companies. Strategic collaborations, licensing and selective acquisitions have been part of Amgen’s approach to broaden its pipeline and reach.
Amgen is governed by an executive leadership team and board of directors and emphasizes long-term investment in R&D, manufacturing quality and regulatory compliance. Its public-facing strategy highlights innovation in biologics, efforts to expand access to therapies worldwide, and ongoing development programs across multiple therapeutic areas.
